U.S. may lose chance to pass national drug trace plan

WASHINGTON (Reuters) - A proposed law calling for healthcare companies to build a U.S. system for tracking medications to minimize the threat of fake drugs is in jeopardy, thanks to arguments over cost and a looming deadline. The U.S. Food and Drug Administration said earlier this year that counterfeit vials of cancer drug Avastin were sold to dozens of medical practices across the country, sparking new fears about the safety of the drug supply. ...